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Background: Annexin V, a 35.8 kDa intracellular protein, is a Ca+2- dependent phospholipid binding protein with
high affinity to phosphatidylserine (PS), which is a well-known hallmark of apoptosis. Annexin V is a sensitive probe
for PS exposure upon the cell membrane, and used for detection of apoptotic cells both in vivo and in vitro.
Large-scale production of recombinant human annexin V is worth optimization, because of its wide use in nuclear
medicine, radiolabeled with 99mTc, for the evaluation of cancer chemotherapy treatments, and its use in identification
of apoptotic cells in histologic studies. Here we describe the high-yield production of a tag-free version of human
annexin V recombinant protein by linear fed-batch cultivation in a bioreactor.
Results: We cloned the human ANXA5 coding sequence into the pET-30a (+) expression vector and expressed
rhANXA5 in batch and fed-batch cultures. Using E. coli BL21 (DE3) in a semi-defined medium at 37°C, pH 7 in fed-batch
cultures, we obtained a 45-fold increase in biomass production, respective to shaker cultivations. We developed a
single-step protocol for rhANXA5 purification using a strong anion-exchange column (MonoQ HR16/10). Using
these procedures, we obtained 28.5 mg of homogeneous, nontagged and biologically functional human annexin
V recombinant protein from 3 g wet weight of bacterial cells from bioreactor cultures. The identity and molecular
mass of rhANXA5 was confirmed by mass spectrometry. Moreover, the purified rhANXA5 protein was functionally
evaluated in a FITC-annexin V binding experiment and the results demonstrated that rhANXA5 detected apoptotic
cells similarly to a commercial kit.
Conclusions: We describe a new fed-batch method to produce recombinant human annexin V in large scale,
which may expand the commercial utilities for rhANXAV to applications such as in vivo imaging studies.
Keywords: Recombinant human annexin v, Fed-batch cultivation, Large-scale, Apoptosis detectionBackground
Annexin V, formerly known as human placental anticoa-
gulation protein, is a member of a family of calcium-
dependent phospholipid binding proteins [1] that binds
preferentially to phosphatidylserine (PS), a negatively
charged phospholipid highly enriched in the inner leaflet
of plasma membranes [2]. Annexin V shows minimal cap-
acity to bind phospholipids that are constitutively present* Correspondence: cristiano.bizarro@pucrs.br
†Equal contributors
1Centro de Pesquisas em Biologia Molecular e Funcional (CPBMF), Instituto
Nacional de Ciência e Tuberculose (INCT-TB), Pontifícia Universidade Católica do
Rio Grande do Sul (PUCRS), Av. Ipiranga 6681, 90619-900 Porto Alegre, Brazil
2Programa de Pós-Graduação em Biologia Celular e Molecular, PUCRS, Porto
Alegre 90619-900, Brazil
Full list of author information is available at the end of the article
© 2014 Marder et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orin the outer leaflet of plasma membranes, such as phos-
phatidylcholine and sphingomyelin [1]. During the early
stages of apoptosis, cells expose PS on the surface, which
is specifically recognized by phagocytic cells [3]. The ex-
posed PS residues can be bound selectively by annexin V
with nanomolar to picomolar affinity [4,5]. Because of the
role of apoptosis in the pathophysiology of many diseases,
there is a wide range of current and potentially new
applications for annexin V as an apoptotic marker in
clinical diagnosis [6]. Staining cells simultaneously with
annexin V labeled with the fluorochrome fluorescein
isothiocyanate (FITC) and the non-vital dye propidium
iodide (PI) allows the discrimination among intact cells
(FITC−/PI−) early apoptotic cells (FITC+/PI−) and lateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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combinant human annexin V (rhANXA5) serves as an im-
portant in vivo diagnostic tool when labeled with different
radionuclides, such as iodine-123 (123I) and the metastable
isotope technetium-99 (99mTc) providing a broad range
of imaging applications in apoptosis research, as single-
photon emission computed tomography and auto-
radiography to positron emission tomography [8]. In
nuclear medicine, annexin V radiolabeled with 99mTc or 123I
is used to evaluate the efficacy of cancer therapy and
disease progression or regression [9].
Because of its widespread use as a diagnostic tool,
rhANXA5 is commercially produced in microorganisms
such as Escherichia coli using recombinant DNA tech-
niques [10-13]. To produce rhANXA5 in large scale in
this study, we used E. coli, the most commonly used host
for recombinant protein production [14]. In shake flask
cultures, all components are added at the start of the
cultivation, without the need to monitor or control any
parameter such as pH or the level of dissolved oxygen,
leading to slow growth and low recombinant protein
production [15]. High cell-density culture techniques
have been developed to improve productivity and to pro-
vide advantages such as reduced culture volume, enhanced
downstream processing, reduced wastewater, lower produc-
tion costs and reduced investment in equipment [14]. Fed-
batch cultivation is an effective and simple method [16],
allowing substantial concentrations of glucose, an inexpen-
sive and readily usable carbon and energy source [17]. To
our knowledge, there is currently no protocol available for
a bioreactor-based, large-scale production of rhANXA5.
In this work, we describe a procedure for the production
of 28.5 mg of homogeneous, nontagged rhANXA5 from
3 g wet weight of bacterial cells from bioreactor cultures.
The identity and absence of host contaminants in purified
rhANXA5 was confirmed by LC-MS/MS peptide mapping
experiments. The molecular mass determination of intact
rhANXA5 confirmed the integrity of the purified protein.
Additionally, the produced rhANXA5 protein was shown
to be functional in a bioassay for in vitro apoptosis/necro-
sis detection, in which it performed similarly to a com-
mercially available kit.
Results and discussion
Cloning and expression of rhANXA5
The gene encoding human Annexin V, ANXA5, is located
on human chromosome 4q27 locus and spans a region of
DNA 29 kb in length containing 13 exons and 12 introns.
ANXA5 encodes a 35.8 kDa protein of 320 amino acid resi-
dues in length which is translated from a single mature
transcript of approximately 1.6 kb [18]. The human ANXA5
coding sequence was subcloned into the pET-30a (+) ex-
pression vector to generate the recombinant pET-30a (+)::
ANXA5 plasmid. Both the sequence and the absence ofPCR-introduced mutations in the ANXA5 coding sequence
were confirmed by automated sequencing.
The BL21 (DE3) and C41 (DE3) E. coli strains were
transformed with the pET-30a (+)::ANXA5 construct by
electroporation. The expression profiles were tested in ly-
sogeny broth (LB) and in our semi-defined (SD) medium.
The best results of soluble recombinant protein produc-
tion from shaker cultivation were obtained using the BL21
(DE3) strain in SD medium induced with 1 mM IPTG at
37°C (Additional file 1: Figures S1 and Figure S2).
Bioreactor cultivation
The best growth conditions found in shaker cultivations
were applied to the bioreactor batch and fed-batch cul-
tures. We employed our SD medium and a temperature
of 37°C in all experiments.
Transformed BL21 (DE3) E. coli was grown from a mas-
ter cell bank (MCB) under batch cultivation in 1 L of SD
medium at 37°C monitoring glucose consumption. Within
4 h, glucose was depleted from media, indicating this was
the right time to start feeding. We compared DO-stat, pH-
stat and linear ascending feeding strategies in uninduced
cultures. A biomass concentration of 26.01 g (DCW) L−1
was attained in an uninduced culture using the linear
ascending feeding profile [17]. Lower values for biomass
concentration were obtained using DO-stat (20.15 g
(DCW) L−1) or pH-stat (11.59 g (DCW) L−1) feeding
strategies. Therefore, we selected the linear ascending
feeding strategy for further fed-batch cultivations.
After 4 h of batch cultivation without feeding, the bio-
mass concentration reached 4.71 g (DCW) L−1 (n = 4,
SD = 0.6). We induced rhANXA5 expression in fed-
batch cultivations with linear ascending feeding by add-
ing IPTG to a final concentration of 1 mM. From three
independent fermentations, we obtained a mean value of
27.48 g (DCW) L−1 (SD = 1.96) for the biomass concen-
tration and a total protein content of 4.8 g L−1 (Figure 1).
In contrast, we obtained a biomass concentration of
0.615 g (DCW) L−1 in shaker cultivation (OD600nm =
1.84) after 6 h of culture. This represents a 45-fold in-
crease in biomass concentration.
In an independent bioreactor cultivation, we performed
densitometric analysis of culture samples (in triplicate) to
calculate the product yield (g (rhANXA5) L−1), the prod-
uctivity (g (rhANXA5) L−1 h−1) and the specific yield (g
(rhANXA) g (DCW)−1). rhANXA5 corresponded to 40.6%
(mean value) of the total protein content (n = 3, SD = 0.03)
(Additional file 1: Figure S4). Therefore, we obtained a
product yield of 1.95 g (rhANXA5) L−1 of culture medium,
a specific yield of 0.0715 g (rhANXA5) g (DCW)−1 and a
productivity of 0.065 g (rhANXA5) L−1 h−1, considering the
entire fermentation period (30 h).
Moreover, we can consider the entire procedure, from
bioreactor cultivation to protein purification, and calculate
Figure 1 SDS-PAGE analysis of rhANXA5 expression in
fed-batch cultivations. Recombinant E. coli BL21(DE3) cells were
cultivated in semi-defined (SD) media for 30 h in fed-batch cultivations.
Feeding started 4 h after the beginning of batch cultivation and
rhANXA5 expression was induced after 18 h of cultivation by the
addition of 1 mM IPTG to the cultures. M: Thermo Scientific™ Unstained
Protein MW Marker; lane 1: sample collected immediately before IPTG
induction (18 h culture); lanes 2–7: samples collected after IPTG
induction from 20 h (lane 2), 22 h (lane 3), 24 h (lane 4), 26 h (lane 5),
28 h (lane 6), and 30 h (lane 7) cultures.
Figure 2 SDS-PAGE analysis of rhANXA5 purification steps.
SDS-PAGE (12%) analysis of fractions from different steps of rhANXA5
purification. Each sample lane contains 8 μg of total protein. M
corresponds to Thermo Scientific™ Unstained Protein MW Marker;
lane 1: cells suspended in buffer A (50 mM Tris–HCl, pH 7.2, 10 mM
CaCl2) with no previous centrifugation step; lane 2: supernatant of
cells in buffer A after sonication and centrifugation (for 20 min,
24,400 × g, 4°C); lane 3: cell pellet from the previous centrifugation
suspended in buffer B (50 mM Tris–HCl, pH 7.2, 20 mM EDTA); lane
4: suspension from previous step dialyzed against 2 L of 20 mM
Tris–HCl, pH 8.0 for 3 times, overnight in the first step, followed by two
steps of dialysis 2 h each; lane 5: supernatant after centrifugation of
dialyzed sample (for 30 min, 24,400 × g, 4°C); lane 6: homogeneous
preparation of annexin V eluted from the Mono Q column.
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From four independent purifications, we obtained a mean
value of 28.5 mg of purified rhANXA5 from 3 g wet
weight of cells (n = 4, SD = 6.7). In terms of volumetric
yield, we obtained (mean value) 0.983 g (purified
rhANXA5) L−1 (n = 4, SD = 0.23). The productivity over
the entire fermentation (30 h) was 0.0361 g (purified
rhANXA5) L−1 h−1 (n = 4, SD = 0.0084).
Purification
The overexpressed protein was purified by a single-step
protocol consisting of a strong anion-exchange column
(MonoQ HR16/10). Figure 2 shows the steps of rhANXA5
purification. The target protein eluted at approximately
190 mM of NaCl from a MonoQ HR 16/10 column
(Additional file 1: Figure S3). The eluted protein was
pooled and dialyzed against HEPES 100 mM NaCl pH 7.2,
concentrated using an AMICON ultra-filtration mem-
brane and stored at −80°C in 1 mL aliquots. This puri-
fication protocol yielded 28.5 mg of purified rhANXA5
from 3 g wet weight of cells (n = 4, SD = 6.7).
rhANXA5 identification by mass spectrometry
Homogeneous rhANXA5 samples were desalted and
digested with trypsin, and the peptide mixtures were
analyzed in LC-MS/MS peptide mapping experiments.
A total of 320 spectra were identified with 29 different
peptides derived from rhANXA5 protein. These peptides
covered 80% of the rhANXA5 sequence.
Determination of rhANXA5 molecular mass
The spectra of intact rhANXA5 samples were recorded
with a linear ion trap analyzer. Peaks spanning chargestates 18+ to 39+ were detected (Figure 3a) and the spectra
deconvoluted. We obtained a value of 35,804 Da for the
average molecular mass of rhANXA5 (Figure 3b), consistent
with the post-translational removal of the N-terminal
methionine (theoretical average molecular mass of
35,937 Da with methionine and 35,805 Da without
methionine).
FITC-annexin V binding test
To test the functional activity of purified rhANXA5, we
assayed its ability to detect cells undergoing apoptosis.
We treated B16F10 cells with cisplatin to induce apop-
tosis and after 6 or 12 h, we stained treated cells simul-
taneously with the non-vital dye PI and with rhANXA5
labeled with the fluorochrome FITC. Double staining al-
lows the discrimination between intact cells (FITC−/PI−),
early apoptotic cells (FITC+/PI−) and late apoptotic or
necrotic cells (FITC+/PI+) [7]. The ability of FITC-labeled
rhANXA5 to detect apoptotic cells was compared with a
commercial kit from BD. We performed dose curve experi-
ments with different concentrations of cisplatin and stained
treated cells for 6 h (Figure 4a) or 12 h (Figure 4b) after
treatment. We obtained similar results using our home-
made kit (QuatroG) or the commercial kit at different times
after treatment (6 h or 12 h) and concentrations of cisplatin
(20, 40, 80 and 160 μg/mL), indicating that purified
rhANXA5 is functionally active. Dot plot representations
Figure 3 Determination of rhANXA5 molecular mass by mass spectrometry. a) ESI-FTMS spectra of rhANXA5 showing charge state distribution
spanning from 18+ to 39+. b) Experimentally determined value of 35,804 Da for rhANXA5 average molecular mass after spectra deconvolution.
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treatment clearly show differences in the distribution
of FITC/PI cell populations between untreated cells
(negative control), cells treated with 40 μg/mL and
cells treated with 160 μg/mL of cisplatin (Figure 5).Figure 4 Analysis of apoptosis in B16F10 cells. Flow cytometric
analysis of apoptotic cells stained with both FITC-labeled annexin V
and PI using the BD Biosciences kit or a homemade kit (QuatroG)
containing purified rhANXA5 conjugated with FITC. Apoptosis was
induced by treating B16F10 cells with 20, 40, 80 or 160 μg/mL of
cisplatin and double staining was performed after 6 h (a) or 12 h (b).Conclusions
Fed-batch cultivations represent an alternative to shaker
cultivations, allowing control of process variables and
improvement on biomass concentration and product
yields [15]. A chimeric protein containing the C-terminus
of hirudin fused to annexin V was previously expressed in
large scale using fed-batch fermentation [19]. However, to
the best of our knowledge, this is the first report of a scale
up of rhANXA5 production.
Recombinant protein production methods must con-
tinuously be improved to meet commercial demands
[14,20]. In this work, we produced 28.5 mg of purified
recombinant human annexin V from 3 g wet weight
of cells (n = 4, SD = 6.7) obtained in fed-batch cultures
induced with IPTG. Moreover, this protocol generated
a yield of homogeneous rhANXA5 (mean value) of
0.983 g (purified rhANXA5) L−1 (n = 4, SD = 0.23). The
productivity over the entire fermentation (30 h) was
0.0361 g (purified rhANXA5) L−1 h−1 (n = 4, SD = 0.0084).
rhANXA5 could be commercially distributed to sev-
eral research groups and to radiopharmaceutical com-
panies. The use of fluorescence-labeled annexin V to
identify apoptotic cells is currently limited to histologic
and cell-sorting studies performed in vitro. Its use for
in vivo imaging studies is hampered mainly by cost is-
sues. Hence, production in large scale may expand the
commercial utilities for rhANXA5, reducing costs and
allowing a greater access of the scientific and physician
community to this product.
Methods
Strains and plasmids
The E. coli strains BL21(DE3) and C41(DE3) were pur-
chased from Novagen® (EMD Biosciences, Inc., Madison,
WI, USA) and Lucigen Corporation (Middleton, WI,
USA), respectively. The PCR-Blunt® cloning vector was
Figure 5 Representative dot plots of flow cytometric analysis. Dot plots of B16F10 cells stained with both FITC-labeled annexin V and PI
using the BD Biosciences kit or a homemade kit (QuatroG) 12 h after inducing apoptosis with 0 μg/mL, 40 μg/mL or 160 μg/mL of cisplatin. The
upper and lower right quadrants of each dot plot represents cells at late (PI and annexin V positive) and early (annexin V positive only) apoptosis.
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the pET-30a (+) expression vector was from Novagen®.
Molecular cloning of rhANXA5
Oligonucleotides were designed based on the human
ANXA5 coding sequence in the GenBank (accession
number: NM_001154.3) National Institute of Health
(NIH) genetic sequence database [18]. Specific primers
were designed to contain NdeI (forward primer: 5’ GCG
CAT ATG GCA CAG GTT CTC AGA GGC ACT 3’)
and HindIII (reverse primer: 5’ GCG AAG CTT TTA
GTC ATC TTC TCC ACA GAG C 3’) restriction sites
(italics). The human ANXA5 gene sequence was PCR-
amplified from a human blood cDNA sample.
The amplified ANXA5 coding sequence was cloned into
the PCR-Blunt® vector, cleaved with NdeI and HindIII re-
striction endonucleases (New England BioLabs®, Ipswich,
MA, USA) and subcloned into the pET-30a (+) expression
vector, previously digested with the same restriction en-
zymes, to generate the pET-30a (+)::ANXA5 plasmid. The
cloned ANXA5 sequence was confirmed by automated
DNA sequencing.
Media preparation
Lysogeny broth (LB) (tryptone, 10 g L−1; yeast extract,
5 g L−1; NaCl, 10 g L−1) was sterilized by autoclaving(30 min at 121°C). LB medium was used for shake-flask
cultivation and for inoculum development of bioreactor
cultivations.
Semi-defined medium (SD) [21] was used for shake-
flask cultivations as well as fed-batch bioreactor cultiva-
tions, as both initial batch and also feeding media (with
varied glucose and MgSO4 concentrations). SD medium
contains 0.5 g L−1 NaCl (a), 1 g L−1 NH4Cl (b), 20 g L
−1
yeast extract (c), 6 g L−1 Na2HPO4 (d), 3 g L
−1 KH2PO4
(e), 1 μg L−1 thiamine (f ), 1 mM MgSO4 (g), 0.1% trace
solution (h), and 0.1 mM CaCl2 (i). For both shake-flask
and bioreactor fed-batch cultivations (initial batch cul-
ture), SD medium was supplemented with glucose to a
final concentration of 5 g L−1 (j). Components (a) to (e)
were assembled and sterilized together by autoclaving
(30 min at 121°C), while components (g) to (i) were ster-
ilized separately by autoclaving and added under aseptic
conditions. Thiamine solution (f ) was filter-sterilized.
Trace solution (h) contained 2.8 g L−1 FeSO4, 2 g L
−1
MnCl2, 2 g L
−1 CaCl2, 0.26 g L
−1 CuCl2, and 0.3 g L
−1
ZnSO4. For feeding medium in bioreactor cultivations,
SD medium was supplemented with glucose (final con-
centration of 300 g L−1) and MgSO4 (40 mM). To pre-
pare this feeding medium, we mixed equal parts of a 2x
concentrated SD medium and a 600 g/L glucose stock
solution, both sterilized separately. SD medium used in
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of Antifoam 204 (Sigma-Aldrich, São Paulo, SP, Brazil) per
liter of culture. Both LB and SD media were supplemented
aseptically with filter-sterilized kanamycin to a final concen-
tration of 30 μg mL−1.Shake-flask cultivation
E. coli BL21(DE3) and C41(DE3) strains were transformed
with the pET-30a (+) vector or the pET-30a (+)::ANXA5
recombinant plasmid by electroporation. Transformant
colonies were selected on LB agar plates containing
30 μg mL−1 kanamycin [22]. Isolated colonies were se-
lected and grown overnight (at 37°C and 180 rpm) in
5 mL of LB supplemented with 30 μg mL−1 kanamycin.
To compare the expression profile with different strains
(BL21(DE) or C41(DE3)) or media (LB or SD medium),
saturated cultures were inoculated in 50 mL of LB or SD
medium for shake-flask cultivations and grown at 37°C
and 180 rpm to an optical density (OD600 nm) of 0.4–0.6.
At this growth stage, we induced rhANXA5 expression by
adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a
final concentration of 1 mM. At 3, 6, 9 or 24 h after induc-
tion, cells were harvested by centrifugation (11,800 g) for
30 min at 4°C, and the pellet was stored at −20°C. The ex-
pression of the recombinant soluble protein was con-
firmed by 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) visualized by Coomassie®
Brilliant Blue R-250 staining. For biomass measurements
from shake-flask cultures, isolated colonies were selected
and grown overnight (at 37°C and 180 rpm) in 10 mL of
LB supplemented with 30 μg mL−1 kanamycin and inocu-
lated in 500 mL of SD medium. Inoculated cultures were
grown (37°C and 180 rpm) to an optical density (OD600 nm)
of 0.4–0.6, rhANXA5 expression was induced by the
addition of IPTG to a final concentration of 1 mM, and
cells were harvested after 6 h of IPTG induction.Inoculum development for bioreactor cultivation
A master cell bank (MCB) of transformed E. coli BL21
(DE3) cells containing the pET-30a (+)::ANXA5 recom-
binant plasmid was prepared in 50% glycerol and stored
at −80°C. For inoculum development, 150 μL of E. coli
BL21(DE3) MCB cells (stored at −80°C) were grown
overnight at 180 rpm and 37°C in 1 L flasks containing
250 mL of LB medium supplemented with 30 μg mL−1
kanamycin. The final optical density (OD600) for each
pre-inoculum culture was determined spectrophotomet-
rically. For each experiment, we calculated and collected
the initial volume of pre-inoculum culture needed to
start bioreactor cultivation with an initial OD600 of 0.1.
Collected aliquots were diluted in LB medium to a final
volume of 100 mL before inoculation in 900 mL of SD
medium for bioreactor cultivation.Bioreactor cultivation
Batch and fed-batch culture experiments were conducted
in a BIOSTAT® B Plus bioreactor (Sartorius Stedim,
Goettingen, Germany) with two 2 L stirred tanks, filled
with 1 L of SD medium each, at 37°C, pH 7.0 and supple-
mented with kanamycin. For pH control, 12% (v/v) am-
monium hydroxide and 10% (v/v) phosphoric acid were
employed. The bioreactor was equipped with two Rushton
turbines and with agitation, aeration, temperature and pH
controllers. A polarographic electrode was used to meas-
ure the dissolved oxygen concentration (DOC) in the
culture. The pO2, pH, stirrer speed, base and acid con-
sumption and aeration rate were measured online and re-
corded by an external data acquisition and control system
(Sartorius Stedim). Feeding was implemented using the
bioreactor proprietary software micro-DCU system v. 0.63
(Sartorius Stedim) that allows controlling a peristaltic
pump for feeding medium addition. The flow rate varied
linearly from 0.066 mL min−1 (starting after 4 h of batch
culture) to 0.594 mL min−1 after 26 h of feeding (30 h of
bioreactor cultivation). In batch cultures, the DOC was
maintained at 30% by cascading agitation (400–1000 rpm)
with constant aeration rate (1vvm), and the process was
finished when the biomass reached stationary phase.
Fed-batch cultivations were started as batch cultures
with feeding starting at 4 h of cultivation (approximately
OD600nm 16.0) with SD as feeding medium (see subsec-
tion "Media preparation"). Different feeding strategies
were tested. In DO-stat feeding fermentations, with
DOC setpoint at 30%, the agitation rate was maintained
at 800 rpm (after feeding initiation). In fed-batch fer-
mentations with a linear ascending or pH-stat feeding,
the DOC was maintained at 30% by cascading agitation
(400–1000 rpm) with constant aeration rate (1 vvm).
For linear ascending feeding profile we used the fol-
lowing equation:
F ¼ at þ b
where F is the feeding rate (mL min−1), t the cultiva-
tion time after initiation of the fed-batch culture (min)
and, a and b are constants for the linear ascending
feeding profile [23].
Analytical methods
Samples were withdrawn periodically for quantitative ana-
lysis along the cultivation. Cell growth was monitored by
measuring the optical density at 600 nm (OD600 nm) in a
spectrophotometer. One optical density unit was found to
be equivalent to 0.3342 g L−1 of dry cell weight by gravimet-
ric quantitation. Glucose concentration in the medium was
measured with a glucose analyzer (model 2700 select,
Yellow Springs Instruments, Yellow Springs, OH, USA).
Acetate concentration was determined by high performance
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São Paulo, Brazil) equipped with an Aminex HPX-87H
column (Bio-Rad Laboratories, Hercules, CA, USA), using
0.005 M H2SO4 as mobile phase and a UV-detector. The
protein expression was analyzed by 12% SDS-PAGE
stained with Coomassie® Brilliant Blue R-250 staining. The
annexin V protein produced was quantified using the
Qubit® Protein Assay Kit (Invitrogen™, Life Technologies,
São Paulo, SP, Brazil) and a Qubit® 2.0 Fluorometer
(Invitrogen™).
Purification
ANXA5 recombinant protein was purified using a Fast
Performance Liquid Chromatography (FPLC) ÄKTA
Purifier System (GE HealthCare©). All chromatographic
steps were carried out at 4°C. Sample elution was moni-
tored by UV detection at 215, 254 and 280 nm and frac-
tions were analyzed by 12% SDS-PAGE. According to a
previous report [24], frozen cells (3 g wet weight) were
suspended in 30 mL of buffer A (50 mM Tris HCl,
10 mM CaCl2 pH 7.2) and incubated with 1 mM of phe-
nylmethanesulfonylfluoride for 30 min at 4°C. The cells
were disrupted by sonication (eight pulses of 10”) and cen-
trifuged at 38,900 g for 30 min. The supernatant was dis-
carded and the pellet was completely dissolved in 30 mL
of buffer B (50 mM Tris HCl, 20 mM EDTA pH 7.2),
stirred for 30 min at 4°C, and clarified by centrifugation at
38,900 g for 30 min at 4°C. The supernatant was dialyzed
against 20 mM Tris HCl pH 8.0 (3 × 2 L, 3 h each). Re-
sidual precipitate was removed by centrifugation (38,900 g
for 20 min) and the supernatant was loaded on a MonoQ
HR 16/10 anion exchange column (GE Healthcare) previ-
ously equilibrated with 20 mM Tris HCl pH 8.0. Protein
was eluted with 25% linear gradient of 20 mM Tris HCl,
1 M NaCl pH 8.0 at 1 mL min−1 flow rate. Homogeneous
rhANXA5 was eluted at approximately 190 mM NaCl.
Fractions containing homogeneous rhANXA5 were
pooled, dialyzed against 20 mM N-2-hydroxyethylpipera-
zyne-N’-2-ethanesulfonic Acid (HEPES), 100 mM NaCl
pH 7.2 and concentrated using an AMICON (Millipore
Corporation, Bedford, MA, USA) ultra-filtration mem-
brane (MWCO= 10 kDa), and stored at −80°C. Protein
concentration was determined with Qubit® Protein Assay
Kit using a Qubit® 2.0 Fluorometer.
rhANXA5 identification by mass spectrometry
rhANXA5 preparations (1 nmol) were desalted and sub-
jected to proteolytic degradation using trypsin. The resul-
ting peptides were separated by chromatography using
15 cm capillary columns (150 μm i.d., Kinetex C18 core-
shell particles, Phenomenex, Inc., Torrance, CA, USA)
and a nanoLC Ultra 1D plus equipment (Eksigent,
Redwood City, CA, USA). Separated peptides were ana-
lyzed using an LTQ-Orbitrap hybrid mass spectrometer(Thermo Fisher Scientific Inc, Waltham, MA, USA). The
chromatographic method used a step gradient from mo-
bile phase A (0.1% formic acid in water) to mobile phase
B (0.1% formic acid in acetonitrile): 0–2% B over 5 min;
2–10% B over 3 min; 10–60% B over 60 min; 60–80% B
over 2 min; 80% B isocratic for 10 min; 80–2% B over
2 min; and 2% B isocratic for 8 min. We performed
MS/MS fragmentation using collision-induced dissoci-
ation (CID) with an activation Q of 0.250, an activation
time of 30.0 ms, and an isolation width of 1.0 Da. Using
the Proteome Discoverer software (v. 1.3), we compared
experimentally obtained MS and MS2 spectra with the
in silico trypsin digestion of the human proteome. We
allowed a precursor tolerance of 10 ppm, a fragment toler-
ance of 0.8 Da, static carbamidomethylation on cysteines,
and oxidation on methionine residues. We restricted our
analysis to matches with an Xcorr score > 2.0 for doubly
charged ions and Xcorr score > 2.5 for triply charged ions.
Determination of rhANXA5 molecular mass
Purified rhANXA5 samples were desalted, reconstituted
in acetonitrile 50%/MilliQ-water 49%/formic acid 1%
and directly injected using a 500 μL syringe (Hamilton
Company, Reno, NV, USA) in a static mode into an
IonMax electrospray ion source. The electrospray source
parameters were as follows: positive ion mode, 4.5 kV of
applied voltage to the electrospray source, 5 arbitrary
units (range 0–100) of sheath gas flow, 45.6 V of capil-
lary voltage, 250°C of capillary temperature, and 238.8 V
of tube lens voltage. Full spectra (600–2000 m/z range)
were collected on a Thermo Orbitrap Discovery XL in
profile mode using the linear ion trap analyzer (ITMS
mode). The average spectrum was processed with the
software MagTran [25] for charge state deconvolution.
FITC-annexin V binding test
To confirm the ability of rhANXA5 to detect cells
undergoing apoptosis, we labeled rhANXA5 with the
FluoroTag™ FITC Conjugation Kit (Sigma-Aldrich®). Our
home-made kit also contained PI solution (Sigma-Aldrich®)
and a 10 × binding buffer (0.1 M HEPES-NaOH pH 7.4,
1.4 M NaCl, 25 mM CaCl2). B16F10 melanoma cells
(4X104), a kind gift from Dr. Peter Henson (National Jewish
Center for Immunology, Denver, CO, USA) were cultured
in Dulbecco's Modified Eagle's Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), gentamicin
80 mg L−1 (Novafarma, Anápolis, Brazil), and Fungisone
5 mg L−1 (Bristol Myers Squibb, New York, NY, USA).
To induce apoptosis, the cells were treated with cisplatin
(Libbs, Embu, SP, Brazil) at different concentrations (0, 40,
80 and 160 μg/mL) and after 6 or 12 h, the cells were
stained with our home-made kit or with a commercial
kit from BD Biosciences (FITC Annexin Apoptosis
Detection Kit II, BD Biosciences, San Diego, CA, USA).
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http://www.biomedcentral.com/1472-6750/14/33Cells were stained at a concentration of 105 cells mL−1
in 100 μL of 10X Binding Buffer using 5 μL of PI and
5 μL of rhANXA5 conjugated with FITC (home-made
kit) or 5 μL of annexin-FITC from FITC Annexin
Apoptosis Detection Kit II. All data were collected in a
FACSCanto II flow cytometer (BD Bioscience) and
analyzed using FlowJo software (Tree Stat, San Carlos,
CA, USA).
Availability of supporting data
Supporting data are included in an additional file.
Additional file
Additional file 1: Figure S1. SDS-PAGE analysis (12%) of samples from
shaker cultivations of Escherichia coli BL21(DE3) and C41(DE3) strains in
lysogeny broth (LB) and in our semi-defined (SD) media. M - Thermo
ScientificTM Unstained Protein MW Marker; Lanes 1 and 5 - pET-30a(+)
(empty vector) without IPTG induction; lanes 2 and 6 - pET-30a (+)::ANXA5
without IPTG induction; lanes 3 and 7 - pET-30a (+) (empty vector) after 6h
of IPTG induction; lane 4 - pET-30a(+)::ANXA5 after 3h of IPTG induction;
lane 8 - pET-30a (+)::ANXA5 after 6 h of IPTG induction. a) C41(DE3) and
LB. Overexpression of pET-30a (+)::ANXA5 in E. coli C41(DE3) strain using LB
media. b) BL21(DE3) and LB. Overexpression of pET-30a (+)::ANXA5 in E. coli
BL21(DE3) strain using LB media. c) C41(DE3) and SD. Overexpression of
pET-30a (+)::ANXA5 in E. coli C41(DE3) strain using SD media. d) BL21(DE3)
and SD. Overexpression of pET-30a (+)::ANXA5 in E. coli BL21(DE3) strain
using SD media. Figure S2. Densitometric analysis of lanes 4 and 8 from
Figure S1d. Figure S3. rhANXA5 purification in MonoQ HR16/10 column.
(a) Eluted fractions from MonoQ HR16/10 were analysed by SDS-PAGE
(12%). M corresponds to Unstained Protein MW Marker (Fermentas); Lane
1 corresponds to crude extract; Lanes 2–12 corresponds to MonoQ HR16/10
elution fractions. (b) Chromatogram of eluted fractions. rhANXA5 was eluted
in fractions 118 to 125 (inlet). Figure S4. SDS-PAGE densitometric analysis of
rhANXA5 expression in fed-batch cultivations. M: Thermo Scientific™
Unstained Protein MW Marker; Lanes 1–3: samples collected at 30 h of
culture (triplicate). rhANXA5 corresponded to (1) 45.3%, (2) 38.6% and (3)
37.9% of total protein content.
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